Namal Nawana is a business leader and Healthcare entrepreneur with a particular focus in the Medical Devices and Diagnostics industry. Mr. Nawana is Chairman and Founder of Sapphiros.
Mr. Nawana has extensive experience leading global public companies and was formerly Chief Executive Officer and a member of the Board of Directors of Smith & Nephew Plc, based in the United Kingdom and Chief Executive Officer and member of the Board of Directors of Alere Inc, a NYSE listed company, until its $8 billion acquisition by Abbott Laboratories in 2017. Before joining Alere, he spent more than 15 years at Johnson & Johnson in progressively senior leadership roles globally, including the role of Worldwide President of Johnson & Johnson’s multibillion dollar DePuy-Synthes Spine business.
Mr. Nawana is a member of the Board of Directors of Hologic, Inc. a Nasdaq listed company and past board member of Advamed and Advamed -Dx the peak industry associations of the Medical Device and Diagnostics industries. Mr. Nawana is the Founder of Neoenta LLC, a private company with venture and design and development interests in Healthcare. He is a co-founder of Innovoyce, a voice health company as well as Graphene-Dx, an in-vitro diagnostics company.
Mr. Nawana holds an undergraduate degree in Mechanical Engineering and a Master’s degree in Medical Science from the University of Adelaide, South Australia, as well as an MBA from Henley Management College.
Mohammed is a serial entrepreneur with multiple successful exits of software companies he founded. Mohammed is the co-founder and Director of the Board of GrapheneDx. He was the founder and CEO of Rite Taste, LLC, which merged with GrapheneDx in 2020. Leading Rite Taste, he assembled a team of internationally recognized scientists in nanotechnology, molecular biology, biochemistry, mechanical/industrial design and software engineers to create the electro-chemical assay platform that GrapheneDx is now developing.
Prior to Rite Taste, Mohammed was the CEO of Access International Software Corp, a company commercializing a fundraising software. The company was eventually acquired in 2015.
Mohammed was also the CEO of ADMINS, Inc., a Cambridge-based company commercializing a Municipal Fund Accounting Software, that was sold in 2016.
Mohammed holds a Master in Computer, Information and Control Engineering from the University of Michigan, Ann Arbor, MI, as well as an MBA from Suffolk University, Boston, MA.
Paresh currently manages his private investment office, Sandstone Investments.
From 2005-2014, Paresh was the founder and Managing Partner of Sandstone Capital, a $1.5B+ investment fund focused on long-term investments in public and private companies in Asia. Sandstone invested in a wide range of industries with a focus on pharmaceuticals, financial services and technology.
Prior to Sandstone, Paresh was the founder of Sparta Group, a $5b+ family office for two technology entrepreneurs. Paresh’s more notable private investments include Bharat Financial (IPO 2010), A123 Systems (IPO 2009), Tejas Networks (IPO 2014), AU SFB (IPO 2014), Relicore (M&A 2006), Airvana (IPO 2007), Flipkart (M&A 2014).
More recently Paresh co-founded VelocityDx which is developing and distributing high fidelity rapid diagnostics to global markets, primarily for COVID-19. Paresh is also a seed investor in GrapheneDx which is developing high precision diagnostic technologies on microprocessors.
Paresh has served on the board of several public and private businesses in the US and India. Paresh also served as a director for Harvard Business School India, was a founding member of the South Asia Initiative at Harvard University, and currently is Chairperson of the Investment Committee at the Meadowbrook School of Weston.
Paresh is also an Executive Producer of The Gamechangers Film. Paresh has an MBA from the Harvard Business School and a BA from Boston College.
Tom Ruby is the Chief Executive Officer and member of the Board of GrapheneDx, Inc.
Prior to joining GrapheneDx, Tom was Chief Executive Officer of InnoVoyce, LLC, a medical company focused on voice health, where he led the company through its first rounds of equity financing.
Previously, Tom was an Associate Partner in the McKinsey & Company where he worked with global Biotech and Medical Devices companies on a wide range of commercial and corporate topics to help them successfully bring innovative solutions to patients.
Prior to joining McKinsey in 2012, Tom co-founded Miret Surgical, a surgical device start-up, that successfully developed an FDA-approved new laparoscopic surgery technology.
From 2007 to 2012, Tom was a postdoctoral scholar in Immunology and Microbiology at Stanford University. Tom holds a PhD in Molecular Biology and Genomics from University Paris XI.